28 October 2021>: Clinical Research
Adverse Side Effects Associated with Corticosteroid Therapy: A Study in 39 Patients with Generalized Myasthenia Gravis
Stephen Johnson 1ABCDEF , Nakul Katyal 2DEF , Naureen Narula 3DEF , Raghav Govindarajan 2ABCDEF*DOI: 10.12659/MSM.933296
Med Sci Monit 2021; 27:e933296
Table 2 Summary of patients’ clinical characteristics* (n=39).
Characteristic | No. of patients (%) |
---|---|
Positive AChR antibody test result | 35 (89.7) |
MGFA class | |
2A | 14 (35.9) |
2B | 13 (33.3) |
3A | 8 (20.5) |
3B | 3 (7.7) |
4A | 1 (2.6) |
Pre-existing comorbidities | |
Anemia | 2 (5.1) |
Asthma | 8 (20.5) |
Atopic dermatitis | 1 (2.6) |
Benign prostatic hypertrophy | 1 (2.6) |
COPD | 16 (41.0) |
Coronary artery disease | 2 (5.1) |
Coronary heart disease | 1 (2.6) |
Depression | 4 (10.3) |
Diabetes | 5 (12.8) |
Gastroesophageal reflux disease | 8 (20.5) |
Hyperlipidemia | 4 (10.3) |
Hypertension | 22 (56.4) |
Hypothyroidism | 6 (15.4) |
Lung cancer | 1 (2.6) |
Pre-diabetes | 1 (2.6) |
Prostate cancer | 1 (2.6) |
Stroke | 4 (10.3) |
Vitamin D deficiency | 1 (2.6) |
None | 2 (5.1) |
Number of comorbidities | |
None | 2 (5.1) |
1 | 12 (30.8) |
2 | 9 (23.1) |
3 | 9 (23.1) |
≥4 | 7 (17.9) |
MG-ADL score | |
2 | 3 (7.7) |
3 | 0 |
4 | 0 |
5 | 1 (2.6) |
6 | 4 (10.3) |
7 | 11 (28.2) |
8 | 15 (38.5) |
9 | 3 (7.7) |
10 | 1 (2.6) |
11 | 1 (2.6) |
* Based on the last recorded value in the patient’s medical charts. AChR – acetylcholine receptor; COPD – chronic obstructive pulmonary disease; MG-ADL – Myasthenia Gravis – Activities of Daily Living; MGFA – Myasthenia Gravis Foundation of America. |